Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,effectOfExchangeRate,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,preMarketChange,preMarketChangePercent,preMarketTime,preMarketPrice,regularMarketChangePercent,regularMarketDayRange,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 14, 2021) 4","Short Ratio (Apr 14, 2021) 4","Short % of Float (Apr 14, 2021) 4","Short % of Shares Outstanding (Apr 14, 2021) 4","Shares Short (prior month Mar 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,IBIO,106150000.0,216010000,2444000,,-8131000,-14000,-8129000,5806000,705000,-7545000,-7545000,,-615000,,,,0,705000,8250000,0,-586000,,-8131000,-8194000,1185000.0,273258000.0,38085000.0,107335000.0,1233000.0,145406000.0,212000.0,-166082000.0,-53000.0,1543000.0,91252000.0,6102000.0,465000.0,-53000.0,31796000.0,110882000.0,16395000.0,232000.0,135000.0,1071000.0,2409000.0,-10449000.0,366000.0,-12956000.0,-74000.0,35084000.0,-1942000.0,13709000.0,-32122000.0,-8419000.0,602000.0,-1500000.0,-228000.0,121000.0,-3117000.0,791000.0,-994000.0,,,104780000.0,en-US,US,EQUITY,True,Delayed Quote,ASE,USD,1.28,1630526400,0.00999999,1.27,1.29,1.25,1597815,1.27,0.0,0.0,451,40,finmb_33000,NYSE American,"iBio, Inc.",USD,4130568,3568300,0.25,0.24271846,1.03 - 2.83,-1.55,-0.5477032,1.03,2.83,1528675200,1613509200,1613509200,1613509200,PRE,us_market,"iBio, Inc.",0,False,False,4,-0.03999996,-3.1249971,1630570244,1.24,0.78740084,1.25 - 1.29,-0.178,-0.21,0.507,1.2571429,0.02285707,0.01818176,1.470942,-0.19094205,-0.12980936,276492800,-6.095238,2.5246546,15,America/New_York,EDT,-14400000,-6.24,,,2.83,1.03,1.2571,1.4709,4.13M,3.57M,216.01M,,215.41M,0.99%,14.19%,16.39M,3.98,7.61%,7.59%,10.86M,,,,,,0.00%,"Jun 10, 2018",,1:10,"Jun 10, 2018","Jun 29, 2020","Dec 30, 2020",0.00%,-920.72%,-14.76%,-44.72%,2.33M,0.02,124.50%,1.64M,-19.16M,-24.14M,-0.1780,,107.65M,0.5,32.76M,30.52,18.17,0.51,-23.14M,-16.32M,Value,10022,Healthcare,43,9,5,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",New York,302 355 0650,NY,4,1609372800,1619740800,8,United States,http://www.ibioinc.com,86400,8,600 Madison Avenue,Biotechnology,Suite 1601
t-1,IBIO,78818000.0,216010000,1762000,,-7534000,-12000,-7533000,5572000,410000,-6924000,-6924000,,-614000,,,,0,410000,7334000,0,-610000,,-7534000,-7599000,1236000.0,237867000.0,37212000.0,80054000.0,1370000.0,117254000.0,180000.0,-157953000.0,-40000.0,24000.0,77543000.0,5046000.0,362000.0,-40000.0,31035000.0,84959000.0,6010000.0,300000.0,238000.0,843000.0,1602000.0,-6017000.0,-452000.0,-6600000.0,-73000.0,36101000.0,251000.0,22431000.0,-32122000.0,-7070000.0,584000.0,-1500000.0,-45000.0,-225000.0,-1525000.0,350000.0,-419000.0,37699000.0,,79913000.0,en-US,US,EQUITY,True,Delayed Quote,ASE,USD,1.28,1630526400,0.00999999,1.27,1.29,1.25,1597815,1.27,0.0,0.0,451,40,finmb_33000,NYSE American,"iBio, Inc.",USD,4130568,3568300,0.25,0.24271846,1.03 - 2.83,-1.55,-0.5477032,1.03,2.83,1528675200,1613509200,1613509200,1613509200,PRE,us_market,"iBio, Inc.",0,False,False,4,-0.03999996,-3.1249971,1630570244,1.24,0.78740084,1.25 - 1.29,-0.178,-0.21,0.507,1.2571429,0.02285707,0.01818176,1.470942,-0.19094205,-0.12980936,276492800,-6.095238,2.5246546,15,America/New_York,EDT,-14400000,-6.24,,,2.83,1.03,1.2571,1.4709,4.13M,3.57M,216.01M,,215.41M,0.99%,14.19%,16.39M,3.98,7.61%,7.59%,10.86M,,,,,,0.00%,"Jun 10, 2018",,1:10,"Jun 10, 2018","Jun 29, 2020","Dec 30, 2020",0.00%,-920.72%,-14.76%,-44.72%,2.33M,0.02,124.50%,1.64M,-19.16M,-24.14M,-0.1780,,107.65M,0.5,32.76M,30.52,18.17,0.51,-23.14M,-16.32M,Value,10022,Healthcare,43,9,5,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",New York,302 355 0650,NY,4,1609372800,1619740800,8,United States,http://www.ibioinc.com,86400,8,600 Madison Avenue,Biotechnology,Suite 1601
t-2,IBIO,55474000.0,216010000,349000,,-3540000,-11000,-3538000,3700000,1120000,-2929000,-2929000,,-615000,,,,0,1120000,4049000,0,-611000,,-3540000,-3603000,1144000.0,206931000.0,37582000.0,56618000.0,1810000.0,94189000.0,140000.0,-150420000.0,-33000.0,24000.0,55112000.0,5236000.0,261000.0,-33000.0,31273000.0,61748000.0,,5624000.0,339000.0,798000.0,1759000.0,-6017000.0,-259000.0,-820000.0,-661000.0,49759000.0,-53000.0,45072000.0,-32122000.0,-3867000.0,563000.0,-1500000.0,-798000.0,-225000.0,-1789000.0,218000.0,-807000.0,127000.0,,56512000.0,en-US,US,EQUITY,True,Delayed Quote,ASE,USD,1.28,1630526400,0.00999999,1.27,1.29,1.25,1597815,1.27,0.0,0.0,451,40,finmb_33000,NYSE American,"iBio, Inc.",USD,4130568,3568300,0.25,0.24271846,1.03 - 2.83,-1.55,-0.5477032,1.03,2.83,1528675200,1613509200,1613509200,1613509200,PRE,us_market,"iBio, Inc.",0,False,False,4,-0.03999996,-3.1249971,1630570244,1.24,0.78740084,1.25 - 1.29,-0.178,-0.21,0.507,1.2571429,0.02285707,0.01818176,1.470942,-0.19094205,-0.12980936,276492800,-6.095238,2.5246546,15,America/New_York,EDT,-14400000,-6.24,,,2.83,1.03,1.2571,1.4709,4.13M,3.57M,216.01M,,215.41M,0.99%,14.19%,16.39M,3.98,7.61%,7.59%,10.86M,,,,,,0.00%,"Jun 10, 2018",,1:10,"Jun 10, 2018","Jun 29, 2020","Dec 30, 2020",0.00%,-920.72%,-14.76%,-44.72%,2.33M,0.02,124.50%,1.64M,-19.16M,-24.14M,-0.1780,,107.65M,0.5,32.76M,30.52,18.17,0.51,-23.14M,-16.32M,Value,10022,Healthcare,43,9,5,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",New York,302 355 0650,NY,4,1609372800,1619740800,8,United States,http://www.ibioinc.com,86400,8,600 Madison Avenue,Biotechnology,Suite 1601
t-3,IBIO,2762000.0,216010000,999000,,-4676000,-9000,-4676000,3161000,96000,-4064000,-4064000,,-616000,,,,0,96000,4160000,0,-612000,,-4676000,-4741000,1204000.0,150774000.0,38263000.0,3966000.0,3006000.0,42220000.0,107000.0,-146882000.0,-33000.0,24000.0,10040000.0,6179000.0,,-33000.0,30688000.0,10304000.0,,75000.0,,,547000.0,-6017000.0,82000.0,-96000.0,-800000.0,10287000.0,38000.0,6403000.0,-32122000.0,-3786000.0,558000.0,-1500000.0,-798000.0,149000.0,-321000.0,63000.0,-69000.0,5642000.0,-2000.0,4125000.0,en-US,US,EQUITY,True,Delayed Quote,ASE,USD,1.28,1630526400,0.00999999,1.27,1.29,1.25,1597815,1.27,0.0,0.0,451,40,finmb_33000,NYSE American,"iBio, Inc.",USD,4130568,3568300,0.25,0.24271846,1.03 - 2.83,-1.55,-0.5477032,1.03,2.83,1528675200,1613509200,1613509200,1613509200,PRE,us_market,"iBio, Inc.",0,False,False,4,-0.03999996,-3.1249971,1630570244,1.24,0.78740084,1.25 - 1.29,-0.178,-0.21,0.507,1.2571429,0.02285707,0.01818176,1.470942,-0.19094205,-0.12980936,276492800,-6.095238,2.5246546,15,America/New_York,EDT,-14400000,-6.24,,,2.83,1.03,1.2571,1.4709,4.13M,3.57M,216.01M,,215.41M,0.99%,14.19%,16.39M,3.98,7.61%,7.59%,10.86M,,,,,,0.00%,"Jun 10, 2018",,1:10,"Jun 10, 2018","Jun 29, 2020","Dec 30, 2020",0.00%,-920.72%,-14.76%,-44.72%,2.33M,0.02,124.50%,1.64M,-19.16M,-24.14M,-0.1780,,107.65M,0.5,32.76M,30.52,18.17,0.51,-23.14M,-16.32M,Value,10022,Healthcare,43,9,5,"iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",New York,302 355 0650,NY,4,1609372800,1619740800,8,United States,http://www.ibioinc.com,86400,8,600 Madison Avenue,Biotechnology,Suite 1601
